The effect of comorbidity on survival and collected CD34+cell counts in autologous hematopoietic stem cell transplant patients

Basit Öğe Kaydı
dc.authoridBİÇİM, SOYKAN/0000-0001-7498-344X
dc.authoridSARICI, Ahmet/0000-0002-5916-0119
dc.authoridErkurt, Mehmet Ali/0000-0002-3285-417X
dc.authoridKAYA, Emin/0000-0001-8605-8497
dc.authoridBAHCECIOGLU, OMER FARUK/0000-0002-4045-4555
dc.authoridGOK, Selim/0000-0003-3179-1899
dc.authoridBERBER, Ilhami/0000-0003-3312-8476
dc.authorwosidBİÇİM, SOYKAN/ACZ-6163-2022
dc.authorwosidSARICI, Ahmet/ABI-7512-2020
dc.authorwosidErkurt, Mehmet Ali/ABI-7232-2020
dc.authorwosidKAYA, Emin/W-2951-2017
dc.authorwosidBERBER, Ilhami/ABI-6231-2020
dc.contributor.authorSarici, Ahmet
dc.contributor.authorErkurt, Mehmet Ali
dc.contributor.authorKuku, Irfan
dc.contributor.authorBahcecioglu, Omer Faruk
dc.contributor.authorBicim, Soykan
dc.contributor.authorKaya, Emin
dc.contributor.authorBerber, Ilhami
dc.date.accessioned2024-08-04T20:50:46Z
dc.date.available2024-08-04T20:50:46Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjective: In this study, we aimed to report the effectiveness of hematopoietic cell transplantation-specific comorbidity index (HCT-CI) and GATMO scores in predicting overall survival (OS) who underwent autologous stem cell transplantation (ASCT). Material and methods: The data of 263 MM and 204 lymphoma patients who underwent ASCT in the last 11 years were retrospectively analyzed. Results: Neutrophil engraftment time, thrombocyte engraftment time and collected CD34+ cell counts were similar in MM patients with HCT-CI 2 (all p 2 tended to be higher than those with HCT-CI 2 was 51.5 months, the estimated median OS of patients with HCT-CI 2 was 9.5 months (p=0.012). When lymphoma patients were divided into four groups according to their GATMO scores, the OS of the four groups was found to be different from each other (p<0.001). Conclusion: HCT-CI and GATMO scores predict OS in lymphoma patients but not MM patients.en_US
dc.identifier.doi10.1016/j.transci.2021.103296
dc.identifier.issn1473-0502
dc.identifier.issn1878-1683
dc.identifier.issue1en_US
dc.identifier.pmid34696982en_US
dc.identifier.scopus2-s2.0-85117695408en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1016/j.transci.2021.103296
dc.identifier.urihttps://hdl.handle.net/11616/100277
dc.identifier.volume61en_US
dc.identifier.wosWOS:000766631700017en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofTransfusion and Apheresis Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAutologous stem cell transplantationen_US
dc.subjectLymphomaen_US
dc.subjectMultiple myelomaen_US
dc.subjectHematopoietic cell transplantation-specific coen_US
dc.subjectmorbidity indexen_US
dc.subjectEngraftment timeen_US
dc.titleThe effect of comorbidity on survival and collected CD34+cell counts in autologous hematopoietic stem cell transplant patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu